Targeting TGFβR2‐mutant tumors exposes vulnerabilities to stromal TGFβ blockade in pancreatic cancer

Huocong Huang(The University of Texas Southwestern Medical Center), Rolf A. Brekken(Southwestern Medical Center)

EMBO Molecular Medicine

October 14, 2019

10.15252/emmm.201910515

Cited by 87

Related Papers

Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo

|Oncogene|2002|317

Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution

|JCI Insight|2019|281

Sitravatinib potentiates immune checkpoint blockade in refractory cancer models

|JCI Insight|2018|111

Phosphorylation of Akt and ERK1/2 Is Required for VEGF-A/VEGFR2-Induced Proliferation and Migration of Lymphatic Endothelium

|PLoS ONE|2011|99

Losartan Slows Pancreatic Tumor Progression and Extends Survival of SPARC-Null Mice by Abrogating Aberrant TGFβ Activation

|PLoS ONE|2012|77